February 4, 2016 – Geneva, Switzerland – The International Generic and Biosimilar Medicines Association (IGBA) represents companies that are actively engaged in the global manufacturing and trading systems for medicines. We support enhanced cooperation between regulators to foster the global trade in medicines, as well as measures aimed at the elimination of barriers to trade in medicines in order to increase access for patients.
The International Generic and Biosimilar Medicines Association (IGBA), representing member associations from the U.S. (GPhA), Canada (CGPA), Japan (JGA), Jordan (JAPM), Europe (EGA), South Africa (NAPM), and Taiwan (TGPA), as well as associate member associations from Australia (GBMA), Brazil (ProGenericos) and Mexico (AMEGI), thank for the opportunity to share our thoughts on the important topic of non-proprietary naming of biological products, including biosimilar products.
JOHANNESBURG, SOUTH AFRICA (November 3, 2015).- The International Generic and Biosimilar Medicines Association (IGBA) welcomed the International Conference on Harmonisation (ICH) reform and the opening of the process to new members, including international industry organisations. The IGBA fully recognises the contribution of the ICH in developing international standards applied to the pharmaceutical industry, including generic and biosimilar manufacturers.
- IGPA becomes IGBA and chairmanship shifts to South Africa
- Global Pharmaceutical Associations Welcome MEDICRIME Convention, Landmark Tool to Curb Global Medicines Counterfeiting
- Statement by the International Generic Pharmaceutical Alliance (IGPA), Regarding the Trans-Pacific Partnership
- IGPA Files Recommendations for USTR 2015 Special 301 Review